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Abstract
Objective The objective of this study was to gain insights into the attitudes of men with lower urinary tract symptoms towards 
deprescribing alpha-blockers and to assess their willingness to participate in a planned discontinuation trial.
Methods This was a cross-sectional questionnaire study. Men aged 30 years and older with lower urinary tract symptoms, 
who were first prescribed an alpha-blocker in 2015 or 2016, were selected from a population-based prescription database. 
We recorded lower urinary tract symptom severity (e.g., International Prostate Symptom Score and Overactive Bladder 
questionnaire) and patient characteristics (e.g., comorbidity and polypharmacy). The linguistically validated Dutch version of 
the revised Patients’ Attitudes Towards Deprescribing (rPATD) questionnaire was also used, to which we added ten specific 
questions on attitudes towards the deprescribing of alpha-blockers. Information about a future discontinuation trial on alpha-
blockers was then provided and participants were asked to indicate if they would participate. We explored the explanatory 
factors for the willingness to participate by logistic regression analyses.
Results Of the 1380 patients in the database, 421 were using an alpha-blocker, and 195 completed the questionnaire. Of 
these, 16 men were excluded because of indwelling catheter use or unknown indication. The mean age of the 179 participants 
was 69.4 (standard deviation 9.2) years. Most men were satisfied with their current therapy, but almost all (93%) were will-
ing to stop the medicine at the request of a doctor. Therefore, most men (61%) were willing to participate in the proposed 
alpha-blocker discontinuation trial. Willingness to stop therapy was affected by patients’ perceptions of the appropriateness 
of alpha-blocker therapy and concerns about stopping that therapy.
Conclusions Although men who use alpha-blockers are generally satisfied with their current therapy, most will participate 
in a discontinuation trial.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 6-019-00712 -6) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Alpha-blockers are the cornerstone of drug treatment for 
male lower urinary tract symptoms (LUTS) [1]. The preva-
lence of moderate-to-severe LUTS varies between 20 and 
25% and it increases with age [2]. In the Netherlands, half of 
men visiting a general practitioner (GP) with LUTS receive 
drug therapy. Over 80% of these men receive alpha-blocker 
therapy, accounting for approximately 270,000 male users 
at a cost of 15 million euros in 2016 [3, 4]. Alpha-blockers 
aim to reduce the muscle tone of the prostate and the bladder 
output resistance by blocking the alpha-1-receptors [5]. The 
major effect of alpha-blockers is measurable within 2 weeks. 
Little is known about the clinical value of the alpha-blocker 
and the duration of prescription. A systematic literature 
review and meta-analysis, performed by the National Insti-
tute for Health and Clinical Excellence, revealed a modest 
decrease in symptom severity of limited clinical relevance 
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Key Points 
This is the first study to have used the linguistically 
validated Dutch version of the revised Patients’ Attitudes 
Towards Deprescribing Questionnaire (rPATD).
Patients appear to be unconcerned about stopping alpha-
blocker therapy and most are willing to stop their treat-
ment at the suggestion of a doctor.
Most alpha-blocker users would be willing to partici-
pate in a discontinuation trial if they were invited and 
patients’ perceptions of the appropriateness of alpha-
blocker therapy, as well as their concerns about stopping 
that treatment, are important to this willingness.
and over with LUTS towards deprescribing alpha-blocker 
therapy. We also wanted to assess the willingness of those 
men to participate in a planned discontinuation trial of 
alpha-blockers and to analyse what factors influenced that 
willingness to participate.
2  Methods
2.1  Study Design and Population
We conducted a cross-sectional questionnaire survey among 
men with LUTS who were receiving alpha-blocker therapy. 
Men were selected from 20 pharmacies collaborating with 
the University of Groningen pharmacy prescription data-
base (IADB.nl). This is a growing database that contains 
prescription data for more than 20 years from approxi-
mately 60 community pharmacies, covering an estimated 
600,000 patients. Registration in the database is irrespective 
of healthcare insurance, age, or sex. Prescription rates in 
the database have been shown to be representative of the 
Netherlands as a whole, and the database is widely used for 
research. Each person is individually tracked throughout the 
database period and prescription records contain informa-
tion on the date of dispensing, the quantity dispensed, the 
dose regimen, the number of days the prescription is valid, 
the prescribing physician, and the Anatomical Therapeu-
tic Chemical code. Each patient has a unique anonymous 
identifier; date of birth and sex are known. Because of the 
high patient-pharmacy commitment in the Netherlands, the 
medication records for each patient are virtually complete, 
except for over-the-counter drugs and medication dispensed 
during hospitalization [12].
We selected patients based on the following criteria: men 
aged at least 30 years; a first alpha-blocker prescription in 
the years 2015 or 2016, prescribed as monotherapy (e.g., 
no combination therapy with 5-alpha reductase inhibitors), 
with an Anatomical Therapeutic Chemical Classification 
code G04CA01–04 (Alfuzosine, Tamsulosine, Terazosine 
and Silodosine) [4], and no prescriptions for these codes 
in the 2 preceding years; and continued use of the alpha-
blocker to the day of invitation. This age group was chosen 
as alpha-blockers are prescribed in these age groups. Invita-
tions were sent from March until September 2017, thus the 
minimum duration of participants taking an alpha-blocker 
was at least 3 months. We excluded men who were using the 
alpha-blocker with an indwelling catheter and for whom we 
could not determine the indication.
Invitations were sent on behalf of the participating phar-
macies, using a patient identification code, from the IADB.nl 
database. Thereafter, we used encrypted respondent numbers 
on the invitations to enable the sending of a reminder after 
2 weeks in case of non-response. Questionnaires could be 
[6]. Prolonged use of alpha-blockers is expensive and may 
be associated with avoidable adverse effects, such as postural 
hypotension, headache, dizziness, fatigue, and ejaculation 
disorder. It is unclear if adverse-effect profiles differ between 
ages, although especially postural hypotension may be more 
prevalent with increasing age.
The Dutch guideline for GPs, issued for the assess-
ment and treatment of LUTS in adult men (aged 18 years 
and older), recommends discontinuing alpha-blockers 
3–6 months after symptom relief from LUTS; however, it 
presented no evidence to support this advice [2]. By con-
trast, it is notable that the national guideline for Dutch urolo-
gists offers no advice about discontinuation, and that the 
European Association of Urology only recommends con-
sidering discontinuation when alpha-blockers are used in 
combination therapy with 5-alpha reductase inhibitors [1, 
5]. As has been investigated in a Dutch pharmacy-based 
study, the discontinuation rate 1 year after the initiation 
of treatment was 60.3–66.1%, without relevant differences 
between prescriptions from urologists and GPs [7]. Discon-
tinuation of the alpha-blocker is important in respect of the 
unknown long-term clinical value, the avoidable side effects, 
and healthcare costs. Although some studies reported on the 
clinical outcome of discontinuation of alpha-blockers, no 
information is available on the attitudes of patients [8, 9].
Discontinuation is appropriate when drugs are ineffective, 
unnecessary, or present a high risk, especially in older patients 
with multi-morbidity who are at risk of polypharmacy. The 
barriers and enablers in so-called deprescribing, the process 
of discontinuing an inappropriate drug under the supervision 
of a healthcare professional, can be studied using the recently 
validated version of the revised Patients’ Attitudes Towards 
Deprescribing (rPATD) questionnaire [10, 11].
The purpose of this cross-sectional questionnaire study 
was to gain insights into the attitudes of men aged 30 years 
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completed on paper or online. The Medical Ethics Com-
mittee of the University Medical Centre Groningen gave 
approval to conduct this study (METc2017/008). In lieu of 
a formal ethics committee, the principles of the Helsinki 
Declaration were followed.
2.2  Data Collection
We recorded the age of each participant and asked them 
to complete four questionnaires: the general and the alpha-
blocker-specific rPATD questionnaires, the International 
Prostate Symptom Index (IPSS) [13], and the Overactive 
Bladder questionnaire (OAB-q) [14]. The IPSS is the main 
questionnaire on the severity of LUTS, used in the field of 
urology. It consists of seven questions on different symp-
toms. Sum scores range from zero to 35 points, and we cat-
egorized scores as mild (1–7 points), moderate (8–19), or 
severe (20–35). The OAB-q is a questionnaire that assesses 
symptom bother and health-related quality of life. This ques-
tionnaire consists of six questions, and scores range from 
zero to 100. We presented the mean score for this question-
naire as no cut-off values are available to categorize symp-
tom severity. We also asked why the alpha-blocker had been 
prescribed (i.e., LUTS, indwelling catheter, or unknown 
indication), the first prescriber of the alpha-blocker (i.e., 
urologist or GP), how many medications were currently 
prescribed and about any diagnosed comorbidities (e.g., car-
diovascular disease, diabetes mellitus, chronic obstructive 
pulmonary disease, prostate or bladder surgery, and prostate 
or bladder cancer). Finally, to assess willingness to partici-
pate in a planned discontinuation trial of alpha-blockers, we 
provided information about the trial in written and video 
formats. Men were subsequently asked to indicate their will-
ingness to participate in such a study if invited (yes or no).
2.2.1  General and Alpha‑Blocker‑Specific rPATD 
Questionnaires
To measure attitudes towards deprescribing, we translated 
and linguistically validated the rPATD questionnaire, using 
the World Health Organization guideline ‘Process of trans-
lation and adaptation of instruments’ [15]. The translated 
questionnaire and the translation and validation process are 
available on request.
The rPATD questionnaire consists of four factors: ‘overall 
burden’, ‘appropriateness’, ‘concerns about stopping’, and 
‘involvement’ [11]. Each factor contains five questions or 
statements (see the Electronic Supplementary Material for 
details). In addition, two general questions are asked: ‘Over-
all, I am satisfied with my current medicines’ (Question A) 
and ‘If my doctor said it was possible, I would be willing 
to stop one or more of my regular medicines’ (Question B). 
All responses were scored on 5-point Likert scales, ranging 
from strongly disagree (1) to strongly agree (5). The rPATD 
was originally developed to collect information on attitudes 
towards deprescribing of drugs in general. Therefore, to 
investigate attitudes towards alpha-blocker deprescribing, 
the questions in the ‘appropriateness’ and ‘concerns about 
stopping’ factors were amended by changing the word ‘med-
icines’ to ‘alpha-blocker’ to create alpha-blocker-specific 
rPATD factors. All participants were asked to answer the 
questions about attitudes towards alpha-blocker deprescrib-
ing, but we requested only participants with three or more 
concomitant drugs to complete the questions about depre-
scribing in general. We felt that deprescribing is especially 
important in the case of polypharmacy; we decided not to 
bother participants with two drugs or fewer with the comple-
tion of the rPATD.
2.3  Analyses
All statistical analyses were performed with IBM SPSS 
Version 23.0 (IBM Corp., Armonk, NY, USA) and all p 
values ≤ 0.05 were considered statistically significant. We 
compared responders to non-responders with respect to age 
and the number of prescribed medications. Mean ages were 
compared by the independent t-test, and the median num-
bers (interquartile range [IQR]) of prescribed medications 
were compared using the Mann–Whitney U test. In the main 
analyses, we assessed the attitudes towards alpha-blocker 
deprescribing and the percentage of men who would be will-
ing to participate in a discontinuation trial.
For the attitudes towards deprescribing, we estimated 
the mean score for each rPATD factor (two alpha-blocker-
specific factors and four general factors, range 1–5) [11]. 
The questions of the appropriateness factors were scored 
inversely, with a higher score indicating that the medication 
was considered appropriate. In lieu of any specific guidelines 
for interpreting the factor scores at the time of analysis, we 
categorized each alpha-blocker-specific rPATD factor and 
each general rPATD factor into ‘disagree’ (mean factor 
score, 1.0–2.4), ‘neutral’ (2.5–3.5), and ‘agree’ (3.6–5.0) 
to describe the attitudes. The results were then expressed 
as percentages.
Finally, we calculated the percentage of participants 
taking alpha-blockers who would be willing to participate 
in a discontinuation trial. To analyse the explanatory fac-
tors for this willingness, we performed univariate logistic 
regression analyses, entering the IPSS, IPSS-quality of life 
(QoL), OAB-q, alpha-blocker-specific rPATD factors, gen-
eral rPATD factors, age, and number of currently prescribed 
medications. The odds ratios (ORs) and corresponding 95% 
confidence interval (CIs) are presented.
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3  Results
3.1  Participants
We identified 1380 patients through the IADB.nl database, 
of whom 421 were still using an alpha-blocker on the day 
of invitation and 195 (46.3%) completed the questionnaire. 
We excluded 16 men because of indwelling catheter use or 
unknown indication, making 179 participants the basis of 
our research. The study flow is shown in Fig. 1, and the 
characteristics of the participants are summarized in Table 1.
The mean age of responders was 69.4 (standard deviation 
9.2) years, compared with 71.8 (standard deviation 10.2) 
years in non-responders (independent t test, p = 0.01). 86% 
was older than 60 years of age. The median number of self-
reported drugs was 4.0 (IQR 2.0–6.0) and 41.6% of patients 
were prescribed more than five drugs. The number of drugs 
did not differ between responders and non-responders 
(Mann–Whitney U test, p = 0.08). Many participants also 
reported one or more chronic diseases (37.2%), with car-
diovascular disease mentioned most frequently. The mean 
IPSS score was 14.4 (standard deviation 6.7), with moderate 
or severe LUTS reported in 57.1% and 26.3% of patients, 
respectively. The median IPSS-QoL and OAB-q scores were 
3.0 (IQR 2.0–4.0) and 30.0 (IQR 16.7–43.3), respectively. 
Most first prescriptions of alpha-blockers were provided by 
a GP (65.7%).
3.2  Attitudes Towards Deprescribing
The attitudes towards deprescribing are shown in Fig. 2. 
Most participants reported being satisfied with their current 
drugs (79.2%), but they were still willing to stop one or more 
of them if their doctor indicated that it was possible (92.7%). 
A small group of participants (12.1%) reported that their 
medications were a burden, and most (91.3%) were highly 
involved with their medications. Regarding appropriateness, 
34.7% considered their general medications to be appropri-
ate and 43.8% considered their alpha-blocker therapy to be 
appropriate. Only 5.6% of all participants reported concerns 
about stopping a drug and 7.3% reported concerns about 
stopping the alpha-blocker.
Fig. 1  Flow diagram of participant selection
Table 1  Characteristics of the study participants (N = 179)
COPD chronic obstructive pulmonary disease, CVD cardiovascular 
diseases, DM diabetes mellitus, GP general practitioner, IPSS Inter-
national Prostate Symptom Index, OAB-q Overactive Bladder ques-
tionnaire, QoL quality of life
a Mean ± standard deviation
b Median (interquartile range)
Age, years 69.1 ± 9.0a
 < 60 (%) 14.0
 60–70 (%) 45.8
 > 70 (%) 40.2
Medication, n 4.0 (2.0–6.0)b





IPSS-QoL score 3.0 (2.0–4.0)b
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3.3  Willingness to Participate in a Discontinuation 
Trial
About two thirds of the alpha-blocker users (61.2%) were 
willing to participate in a discontinuation trial. This willing-
ness was lower when patients considered the alpha-blocker 
to be an appropriate drug (OR 0.47, 95% CI 0.28–0.78) or 
when men reported more concerns about stopping the alpha-
blocker (OR 0.53, 95% CI 0.32–0.87), as shown in Table 2. 
Willingness to participate was higher in men who would be 
willing to stop one or more of their regular medicines at the 
suggestion of their doctor (OR 1.90, 95% CI 1.06–3.42), 
and in men with higher IPSS-QoL scores (OR 1.23, 95% 
CI 1.00–1.51). Ultimately, willingness to participate was 
independent of LUTS severity, as assessed by the IPSS and 
OAB-q scores.
4  Discussion
In this study, we assessed the attitudes of 179 male patients 
with LUTS towards alpha-blocker deprescribing, using the 
recently revised rPATD. Notably, most users were willing 
to stop therapy at the request of a doctor and were prepared 
to participate in a discontinuation trial for alpha-blockers. 
To the best of our knowledge, this is the first study to have 
looked into this topic.
This study has some clear limitations. First, we only 
applied a questionnaire to collect data. The strength of this 
questionnaire is that the main part consisted of separate thor-
oughly validated questionnaires. For the rPATD translation, 
we have followed the guidelines for linguistic validation of 
questionnaires. The response rate in our study hampers firm 
conclusions to be drawn, as selection bias may be present. 
Previous research on deprescribing especially focused on 
older age groups (65 years and older) [16, 17]. We aimed 
to include younger patients, as for this group deprescrib-
ing may also be highly relevant. As the majority of men 
who receive alpha-blockers are aged older than 60 years, the 
group of younger men remained small. However, we believe 
that this first study in this field provides important insights 
in this topic. Future research should include qualitative 
methods, such as interviews or focus groups. In addition, 
the questions about the willingness to stop medication and 
to participate in the discontinuation trial are hypothetical, 
thus further research in clinical practice is needed. Addi-
tional validation of the alpha-blocker-specific rPATD is also 
needed in future research.
In this study, four in five participants were satisfied with 
their current drugs but the majority of men (92.7%) were 
willing to stop one or more drugs when their doctor would 
indicate that this was possible. These findings are in line 
with recent previous studies, focussing on older age groups 
[11, 16, 17]. No previous studies were performed on the 
discontinuation of any urological treatment. We found that 
almost half of all participants in the present study considered 
their alpha-blocker therapy to be appropriate, which was 
larger than the appropriateness scale on other drugs. Only 
a minority of alpha-blocker users had concerns about stop-
ping. In addition, most of the alpha-blocker users reported 
that they were satisfied with their current drugs, yet almost 
all would be willing to stop a medicine if a doctor told them 
it was possible (93%).
If invited, about two thirds of our participants indicated 
that they would take part in a discontinuation trial. Predic-
tive factors for participating in such a trial were ‘considering 
Fig. 2  Outcomes on alpha-
blocker-specific and general 
Dutch version of the revised 
Patients’ Attitudes Towards 
Deprescribing questionnaire 
(rPATD) questionnaire per fac-
tor or question. The percentages 
of participants who agreed, 
disagreed, or were neutral to the 
different factors or questions are 
shown
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the alpha-blocker an appropriate medicine’, ‘having more 
concerns about stopping the alpha-blocker’, and agreeing 
with the statement ‘If my doctor said it was possible, I would 
be willing to stop one or more of my regular medicines’. This 
is in line with previous research in Australia in which the 
willingness to stop a medication is dependent on the appro-
priateness of a medicine and the concerns of stopping it 
[17]. In addition, willingness to discontinue therapy was not 
associated with LUTS severity, though there was a tendency 
for men who were less satisfied with their LUTS (as assessed 
by the LUTS-QoL) to be more willing to participate. We 
felt this finding was counterintuitive, especially given our 
clear explanation to participants that the medication would 
be stopped in any discontinuation trial. A possible explana-
tion for this finding is that patients who are dissatisfied may 
be more willing to try anything different, even discontinua-
tion of the current therapy. Qualitative research may help to 
clarify the issues underlying this finding.
Reducing drug use is important in modern practice, 
especially considering the negative effects of polyphar-
macy. The rate of polypharmacy in our patients (42%) was 
slightly higher than the reported rate in the Dutch popu-
lation aged older than 65 years (i.e., 25–38%) based on 
pharmacy dispensing [18]. This difference is only small, 
but it might reflect selection bias in our study. Polyphar-
macy increases the chance of inappropriate drug prescribing 
with negative clinical and financial consequences [19]. A 
lack of data about the long-term effect of alpha-blocker use 
should prompt clinicians to consider deprescribing whenever 
possible.
To optimize the deprescribing process, it is important 
to study the barriers and enablers associated with that pro-
cess. We added specific questions to study attitudes towards 
alpha-blocker deprescribing and feel that such an approach 
could be invaluable both in future research and in daily 
practice. Indeed, it may be possible to replace the specific 
drug in the questionnaire to allow research into other thera-
pies; however, before the disease-specific component of the 
questionnaire is implemented more widely, additional vali-
dation will be required in a larger cohort. In future research, 
it would be interesting to change the general questions (e.g., 
about satisfaction with medication and willingness to stop at 
the request of a doctor) to questions about a specific medi-
cine. Another important issue in deprescribing is the impact 
of health literacy. In our study, we did not include literacy 
scores, although we attempted to provide all information to 
participants in an easy-to-use format (both printed materials 
and supportive video messages).
5  Conclusions
Patients appear to be unconcerned about stopping alpha-
blocker therapy and most are willing to stop their treatment 
at the suggestion of a doctor. In particular, our data indicate 
that most alpha-blocker users would be willing to partici-
pate in a discontinuation trial if they were invited. Patients’ 
perceptions of the appropriateness of alpha-blocker therapy, 
as well as their concerns about stopping that treatment, are 
important to this willingness.
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Table 2  Predictors of the willingness to participate in a discontinua-
tion trial
CI confidence interval, IPSS International Prostate Symptom Index, 
OAB-q Overactive Bladder questionnaire, OR odds ratio, QoL qual-
ity of life, rPATD Dutch version of the revised Patients’ Attitudes 
Towards Deprescribing Questionnaire
a Question A: Overall, I am satisfied with my current medicines. 
Question B: If my doctor said it was possible, I would be willing to 
stop one or more of my regular medicines
OR 95% CI p value
Alpha-blocker-specific rPATD factor
 Appropriateness 0.47 0.28–0.78 0.004
 Concerns about stopping 0.53 0.32–0.87 0.012
General rPATD factor
 Appropriateness 0.62 0.36–1.07 0.085
 Concerns about stopping 0.66 0.35–1.24 0.200
 Burden 1.28 0.74–2.22 0.378
 Involvement 1.19 0.56–2.57 0.650
 Question  aa 0.73 0.42–1.26 0.253
 Question  ba 1.90 1.06–3.42 0.031





 IPSS-QoL 1.23 1.00–1.51 0.047
OAB-q 1.01 1.00–1.03 0.143
Age, years 0.99 0.96–1.02 0.523




 > 80 0.87 0.27–2.78
Medication 1.10 0.97–1.24 0.127
 < 5 (reference) 0.226
 ≥ 5 1.50 0.78–2.87
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